Method of treating cancer using IL2R beta/common gamma chain antibodies
Anti-CD122 and/or γc antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.
1. A method of treating cancer in a patient suffering from a cancer comprising administering an effective amount of an antibody or antigen binding fragment thereof to the patient, wherein the antibody or antigen binding fragment thereof comprises:
(a) an antigen binding fragment which binds to CD122, the antigen binding fragment having at least one light chain variable region comprising the following CDRs:
LC-CDR1:
(SEQ ID NO: 2)
TGTSSDIGHYDFVS,
LC-CDR2:
(SEQ ID NO: 3)
DINNRPS, and
LC-CDR3:
(SEQ ID NO: 4)
SAYTSSDTLV,
and having at least one heavy chain variable region comprising the following CDRs:
HC-CDR1:
(SEQ ID NO: 36)
NYYMH,
HC-CDR2:
(SEQ ID NO: 37)
AIMPSRGGTSYPQKFQG, and
HC-CDR3:
(SEQ ID NO: 38)
GEYYYDSSGYYY; and
(b) an antigen binding fragment which binds to common γ chain (γc), the antigen binding fragment having at least one light chain variable region comprising the following CDRs:
LC-CDR1:
(SEQ ID NO: 68)
RSSQSLLHSNGYNYLD,
LC-CDR2:
(SEQ ID NO: 69)
LGSNRDS, and
LC-CDR3:
(SEQ ID NO: 70)
MQGTHWPWT,
and having at least one heavy chain variable region comprising the following CDRs:
HC-CDR1:
(SEQ ID NO: 48)
GYYWS,
HC-CDR2:
(SEQ ID NO: 49)
EINHSGSTNYNPSLKS, and
HC-CDR3:
(SEQ ID NO: 77)
SPGGYSGGYFQH.
2. The method of claim 1 , wherein the antibody or antigen binding fragment thereof comprises:
(i) a first CD122 binding polypeptide, comprising:
(a) a binding unit VL1 consisting of the amino acid sequence of SEQ ID NO:1, and
(b) a binding unit VH1 consisting of the amino acid sequence of SEQ ID NO:35; and
(ii) a second γc binding polypeptide, comprising:
(c) a binding unit VL2 consisting of the amino acid sequence of SEQ ID NO:67, and
(d) a binding unit VH2 consisting of the amino acid sequence of SEQ ID NO:76.